# Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)

Source: https://onco.cc/trials/nct04093505/  
OnCo record `nct04093505` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Glasdegib in Acute myeloid leukaemia, run by University Hospital Heidelberg, recorded as terminated on the registry.

## Summary

Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) is a phase 3 interventional study registered as NCT04093505 by University Hospital Heidelberg, with 28 participants recorded, started 2021-04-01 and due to reach its primary completion in 2022-06-15. Interventions recorded: Gemtuzumab Ozogamicin 147, Gemtuzumab Ozogamicin 1, Glasdegib, Placebo Oral Tablet. Conditions recorded: Acute Myeloid Leukemia.

Linked to the drug Glasdegib because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04093505
- Phase: 3
- Setting: Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Intensive Postremission Therapy Double Blinded With or Without Glasdegib in Older Patients With Newly Diagnosed AML
- Sponsor: University Hospital Heidelberg
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT04093505: https://clinicaltrials.gov/study/NCT04093505

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Glasdegib](https://onco.cc/drugs/glasdegib/)

---
JSON: https://onco.cc/api/v1/entities/nct04093505.json